Combining telitacicept and tofacitinib for treating difficult rheumatoid arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the clinical efficacy and safety of telitacicept when used in combination with tofacitinib for patients suffering from refractory rheumatoid arthritis. Participants will be adults aged 18-85 who have not responded to traditional treatments and require this specific combination therapy. The study will monitor treatment outcomes and any adverse effects experienced by the participants over the course of the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-85 years
2. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
3. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
4. Voluntarily provided written informed consent -

Exclusion Criteria:

1. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
2. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
3. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
4. Active tuberculosis or active infectious diseases requiring systemic treatment
5. Pregnancy, lactation, or refusal to use contraception during the study
6. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due to: Non-adherence or Severe adverse reactions
7. Other conditions contraindicating participation per investigator judgment -

Where it's running

• Zhejiang Provincial People's Hospital
  Hangzhou, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Telitacicept plus baricitinib for refractory rheumatoid arthritis

  This test tries combining telitacicept with baricitinib to see if it helps adults with refractory rheumatoid arthritis who haven't improved on other treatments.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07491016

• Heart event risk in people with moderate-to-severe rheumatoid arthritis taking tofacitinib plus a statin versus TNF inhibitors.

  This will test whether taking tofacitinib with a daily statin changes the rate of major heart problems in people 50 and older with moderate-to-severe rheumatoid arthritis and at least one cardiovascular risk factor.

  Recruiting Phase 4 Shaikh Zayed Hospital, Lahore · Lahore, Punjab Province · NCT07554820

• Methotrexate plus tofacitinib for rheumatoid arthritis

  This project will test whether adding tofacitinib to methotrexate helps adults with early, moderate-to-severe rheumatoid arthritis who have a myeloid-stromal synovial pattern.

  Recruiting at 5 sites Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Foshan, Guangdong and 4 other locations · NCT06301373

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.